Your institution may have access to this item. Find your institution then sign in to continue.
Title
News Blast.
Abstract
Presents news briefs concerning the U.S. biotechnology sector as of August 2005. Total amount of the financing completed by Sirna Therapeutics to support the ongoing development of Sirna-027, a chemically modified siRNA to treat age-related macular degeneration; Appointment of Paul Stroobant as vice-president of research at HistoRx; Value of grant money that will be shared by the Bill & Melinda Gates Foundation for the search of new ideas to attack global health challenges.